Table 3 SABR toxicities
Primary lung cancer (N = 109) | Metachronous lung cancer (N = 28) | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|
Total n (%) | Grade 1–2 n (%) | Grade > 2 n (%) | Total n (%) | Grade 1–2 n (%) | Grade > 2 n (%) | Total | Grade 1–2 | Grade > 2 | |
All Toxicities | 59 (54.1%) | 55 (50.5%) | 4 (3.7%) | 12 (42.9%) | 11 (39.3%) | 1 (3.6%) | 0.59 | 0.55 | 0.99 |
Nausea | 0 | 0 | 0 | 1 (3.6%) | 1 (3.6%) | 0 | |||
Pneumonitis | 4 (3.7%) | 3 (2.8%) | 1 (0.9%) | 0 | 0 | 0 | |||
Pneumothorax | 15 (13.8%) | 15 (13.8°%) | 0 | 2 (7.1%) | 2 (7.1%) | 0 | |||
Bronchopulmonary bleeding | 1 (0.9%) | 1 (0.9%) | 0 | 0 | 0 | 0 | |||
Chest wall pain | 2 (1.8%) | 2 (1.8%) | 0 | 1 (3.6%) | 1 (3.6%) | 0 | |||
Rib fracture | 1 (0.9%) | 1 (0.9%) | 0 | 0 | 0 | 0 | |||
Pleural effusion | 6 (5.5%) | 6 (5.5%) | 0 | 1 (3.6%) | 1 (3.6%) | 0 | |||
Lung fibrosis | 12 (11%) | 12 (11%) | 0 | 3 (10.7%) | 3 (10.7%) | 0 | |||
Atelectasis | 6 (5.5%) | 6 (5.5%) | 0 | 1 (3.6%) | 1 (3.6%) | 0 | |||
Dyspnea | 12 (11%) | 9 (8.3%) | 3 (2.8%) | 3 (10.7%) | 2 (7.1%) | 1 (3.6%) | |||